Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01402219
Other study ID # 2008A030201002
Secondary ID
Status Terminated
Phase Phase 4
First received July 25, 2011
Last updated August 27, 2013
Start date November 2008
Est. completion date May 2013

Study information

Verified date August 2013
Source Guangdong General Hospital
Contact n/a
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with chronic kidney disease undergoing coronary angiography.


Description:

To compare the incidence of contrast-induced nephropathy (CIN)(an absolute SCr increase 0.5 mg/dL from baseline) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with chronic kidney disease (serum creatinine level more than 1.5 mg/dL for men and more than 1.3 mg/dL for women or preprocedural estimated glomerular filtration rate(eGFR):15-60 mL/min/1.73 m2) undergoing coronary angiography.


Recruitment information / eligibility

Status Terminated
Enrollment 204
Est. completion date May 2013
Est. primary completion date February 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Provides written Informed Consent and is willing to comply with protocol requirements

- Is =18 years of age

- Has a documented predose serum creatinine level of =1.5 mg/dL for men and = 1.3 mg/dL for women or predose estimated glomerular ?ltration rate (eGFR) of > 15 and = 60 mL/min/1.73 m2, calculated via the MDRD formula from a SCr obtained within 72 hours of enrollment into the study;

- Is referred for cardiac angiography with or without PCI;

- If at the discretion of the Investigator is receiving or will be receiving a prophylactic medication for renal function, the medication is one that is permitted by this protocol (N acetylcysteine, 1200 mg twice daily on the day before and on the day of the cardiac angiography procedure);

- Undergoes or is scheduled to undergo pre, peri, or post procedure hydration permitted by this protocol, i.e.:

- 154 mEq/L sodium bicarbonate solution, administered intravenously at 3 mL/kg/hr for 1 hour before cardiac angiography, followed by an infusion of 1 mL/kg/hr during and out to 6 hours after cardiac angiography, or 0.9% normal saline administered intravenously at 1 mL/kg/hr for 8-12 hours before cardiac angiography, followed by an infusion of 1 mL/kg/hr during and out to 24 hours after cardiac angiography,for the patients with left ventricular ejection fraction <35% or congestive heart failure (class III in accordance with the classification of the New York Heart Association (NYHA), the rate of infusion decreases to half of the above ordinary rate.

Exclusion Criteria:

- Is a pregnant or lactating female. Exclude the possibility of pregnancy: by laboratory testing on-site at the institution (measurement of serum or urine ßHCG) within 24 hours prior to the start of investigational product administration by history (e.g., tubal ligation or hysterectomy, post menopausal with a minimum 1 year without menses)

- Has a history of hypersensitivity to iodine-containing compounds;

- Has unstable renal function (i.e., acute worsening of renal function, as determined by the Investigator, that has been observed in the 7 days prior to enrollment) and/or is in acute renal failure;

- Has end-stage renal disease (i.e., eGFR <15 mL/min/1.73 m2)

- Has severe congestive heart failure (class IV in accordance with the classification of the New York Heart Association (NYHA) ;

- Has uncontrolled diabetes, as determined by the Investigator;

- Has received an iodinated contrast agent within 7 days prior to the administration of the study agent or is scheduled to receive an iodinated contrast agent within 72 hours after administration of the study agent; intake of nephrotoxic drugs within the previous seven days Prior to, during or post the cardiac angiography, is receiving or will be receiving a prophylactic medication to prevent acute kidney injury that is not permitted by this protocol (e.g., theophylline, fenoldopam, etc.);

- Is planned to undergo major surgery (e.g. CABG, valve surgery, etc.) within 48-72 hours after contrast administration;

- Is planned to receive an intravenous diuretic or mannitol as prophylaxis to prevent acute renal injury (Note: chronic administration is allowed);

- Is hemodynamically unstable within 48 hours pre-contrast administration defined as a systolic blood pressure < 90 mmHg or requires pressor or intra-aortic balloon support

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic


Intervention

Drug:
Iopamidol injection 76%
Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
iodixanol
Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution

Locations

Country Name City State
China Guangdong Cardiovascular Institute,Guangdong General Hospital Guangzhou Guangdong

Sponsors (5)

Lead Sponsor Collaborator
Guangdong General Hospital First Affiliated Hospital, Sun Yat-Sen University, Guangzhou General Hospital of Guangzhou Military Command, Nanfang Hospital of Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary contrast-induced nephropathy Contrast-Induced Nephropathy was defined as an increase in serum creatinine of more than 0.5 mg/dl or 25% from the baseline within 48-72 h of contrast exposure 48-72 h Yes
Secondary A relative increase in serum creatinine A relative increase in serum creatinine was defined as more than 25% increase in serum creatinine within 48-72 h of contrast exposure. 48-72 h Yes
Secondary A relative increase in estimated glomerular ?ltration rate (eGFR) A relative increase in eGFR was defined as more than 25% increase in eGFR within 48-72 h of contrast exposure 48-72 h Yes
Secondary An absolute increase in serum creatinine An absolute increase in serum creatinine within 48-72 h of contrast exposure 48-72 h Yes
Secondary Major adverse clinical events Major adverse clinical events: death, requiring renal replacement therapy, 2nd myocardial infarction,target revascularization,acute heart failure, mechanical ventilation,2nd angina,tachyarrhythmia,hypotension,intra-aortic balloon pump and stroke 1 month Yes
Secondary Major adverse clinical events Major adverse clinical events: death, requiring renal replacement therapy, acute myocardial infarction,target revascularization,acute heart failure, mechanical ventilation,2nd angina,tachyarrhythmia,hypotension,intra-aortic balloon pump and stroke 1 year Yes
Secondary An significant increase in serum creatinine An significant increase in serum creatinine was defined as an increase in serum creatinine of more than 1.0 mg/dl from the baseline within 48-72 h of contrast exposure 48-72 h Yes
Secondary Contrast-Induced Acute Kidney Injury Contrast-Induced Acute Kidney Injury was defined as an increase in serum creatinine concentration of more than 0.3 mg/dL from the baseline value at 48 hours after administration of the contrast exposure or the need for dialysis 48 h Yes
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01155128 - Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Phase 4
Completed NCT00962000 - Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate N/A
Completed NCT00560014 - Nutrient Levels Alter Transplant Outcome N/A
Completed NCT03274921 - Biomarkers of Cardiovascular Complications in Chronic Kidney Disease
Completed NCT01964014 - Once-a-day Immunosuppression(CISECON_a_day) Phase 4
Recruiting NCT01728415 - Effects of High-intensity Interval Training in Patients in Hemodialysis N/A
Completed NCT01532297 - Application of Citrate Dialysate in Chronic Haemodialysis N/A
Completed NCT04100551 - Relationship Between Chronic Renal Disease and Risk Stratification for Chronic Ulcer on the on the Diabetic Foot
Recruiting NCT04428827 - Outcome of Patients With Primary Aldosteronism
Completed NCT02299661 - Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease Phase 1
Recruiting NCT02190318 - Residual Renal Function Preservation in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT04157647 - Hemadsorption During and After Cardiopulmonary Bypass to Modulate the Inflammatory Response N/A
Completed NCT04897672 - 2D-speckle Tracking in Pediatric Renal Chronic Disease
Terminated NCT02375711 - Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient N/A
Not yet recruiting NCT04940819 - A Mobile Application Based Dietary Self Management Intervention in Chinese Chronic Kidney Disease Patients N/A
Completed NCT01817322 - Kidney Graft Function Under the Immunosuppression Strategies Phase 4
Completed NCT05383261 - The Impact of the Social Factors and Rehabilitation Program to Address the Implications on Kidney Failure in Hail
Not yet recruiting NCT06439862 - Study of the Quality of Life in School Aged-children With Posterior Urethral Valves
Completed NCT02834026 - Impact of the Cycle Ergometer in Muscle Strength and Pulmonary Function in Patients in Hemodialysis N/A
Completed NCT02072837 - Dyslipidemia-related Risk Factors in Dialysis N/A